1. Expression of Vascular endothelial growth factor (VEGF) and CD34 in different thyroid disorders.
- Author
-
Gogiashvili, L., Gvianishvili, T., Nikobadze, E., Kvachadze, T., Melikadze, E., and Jandieri, K.
- Subjects
VASCULAR endothelial growth factors ,THYROID diseases ,NEOVASCULARIZATION ,DYSPLASIA ,IMMUNOHISTOCHEMISTRY - Abstract
Background: Neovascularization/angiogenesis is crucial for the growth and metastatic spread of neoplasms. It is a key reaction to evaluate the growth potential of neoplasms, a multi-step process related to the modeling of the intercellular matrix, proliferation and migration of endothelial cells. Aim: Study of the vascular density during Hashimoto's Thyroiditis (HT) and Papillary Thyroid Carcinoma (PTC) by immuno-histochemical examination of angiogenesis activity: VEGF, CD34 markers. Methods: The research database is retrospective and prospective tissue samples obtained from patients after total thyroidectomy, lobectomy or partial resection: HT (n=25), PTC (n =10) which studied histologically and immunohistochemically investigated. Results: VEGF expression reduced as compare cases of HT than in PTC. There was no clear association between CD34 and thyroid pathology. Conclusion: VEGF is the most potent inducer of neovascularization, and its increased expression is associated with a poor prognostic outcome in many diseases. It is known that TTF-1 positively regulates VEGF. But it should be noted that, in terms of manifestation time, the action of VEGF is primarily than TTF1, and may be discussed as a predictor of dysplasia and malignant transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2024